Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 383, Issue 3, pp 297–308 | Cite as

Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis

  • Keiichiro Kimachi
  • Hiroshi KajiyaEmail author
  • Shuji Nakayama
  • Tetsuro Ikebe
  • Koji Okabe
ORIGINAL ARTICLE

Abstract

Bisphosphonates have been known to directly inhibit bone resorption and promote apoptosis in mature osteoclasts. Although bisphosphonates have been recognized as the most effective drugs to treat osteoporosis and bone cancer metastasis, the exact effects and mechanism(s) of bisphosphonates on osteoclastogenesis are unclear. The aim of this study was to clarify whether nitrogen-containing bisphosphonates affect recruitment and differentiation in osteoclasts. We examined the effects of zoledronic acid on receptor activator of NF-κB (RANK) expression and cell migration during osteoclastogenesis in two types of osteoclast precursors, RAW264.7 cells and Bone marrow cells (BMCs). Tumor necrosis factor-α (TNF-α) and RANK ligand (RANKL) upregulated RANK expression in RAW264.7 and BMCs in the presence of macrophage colony stimulating factor in a time-dependent manner. Zoledronic acid (30 and 50 μM) had no effect on cell viability in osteoclast precursors after 36 h of cultivation. Zoledronic acid (10 and 30 μM) strongly inhibited TNF-α- and RANKL-induced upregulation of RANK in a dose-dependent manner. The inhibitory effects on RANK expression were likely to be associated with the suppression of the NF-κB pathway, but not other downstream signaling pathways. Zoledronic acid (30 μM) also suppressed the TNF-α- and RANKL-induced migration of precursors by inhibiting the mevalonic acid pathway. Our results suggest that nitrogen-containing bisphosphonates not only inhibit mature osteoclasts but also prevent osteoclast precursors from differentiating and migrating towards inflammatory osteolysis lesions.

Keywords

TNF-α RANKL Zoledronic acid RANK Cell migration Osteoclast precursor cells 

Abbreviations

BRONJ

Bisphosphonate-related osteonecrosis of the jaw

FDPS

Farnesyl diphosphate synthase

FOH

Farnesol

GGOH

Geranylgeraniol

HMG-coA

3-hydroxy-3-methylglutary coenzyme A

M-CSF

Macrophage colony stimulating factor

NFκB

Nuclear factor kappa B

PBS

Phosphate-buffered saline

PCR

Polymerase chain reaction

RANK

Receptor activator of NF-κB

RANKL

Receptor activator of NF-κB ligand

SCCs

Squamous cell carcinoma cells

TNF-α

Tumor necrosis factor-α

TRAP

Tartrate-resistant acid phosphatase

Notes

Grants

This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (no. 21592381 and 20592383) and a Frontier Research Grant.

Conflict of interest

All authors declare no conflict of interest.

References

  1. Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB (2008) Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int J Cancer 123:1733–1740CrossRefPubMedGoogle Scholar
  2. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH (1992) Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 33:1657–1663PubMedGoogle Scholar
  3. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L (1997) A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175–179CrossRefPubMedGoogle Scholar
  4. Boudot C, Saidak Z, Boulanouar AK, Petit L, Gouilleux F, Massy Z, Brazier M, Mentaverri R, Kamel S (2010) Implication of the calcium sensing receptor and the Phosphoinositide 3-kinase/Akt pathway in the extracellular calcium-mediated migration of RAW 264.7 osteoclast precursor cells. Bone 46:1416–1423CrossRefPubMedGoogle Scholar
  5. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337–342CrossRefPubMedGoogle Scholar
  6. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214:149–160CrossRefPubMedGoogle Scholar
  7. Caraglia M, Budillon A, Tagliaferri P, Marra M, Abbruzzese A, Caponigro F (2005) Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets 6:301–323CrossRefPubMedGoogle Scholar
  8. Casey PJ (1995) Mechanisms of protein prenylation and role in G protein function. Biochem Soc Trans 23:161–166PubMedGoogle Scholar
  9. Dannemann C, Grätz KW, Riener MO, Zwahlen RA (2007) Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder. Bone 40:828–834CrossRefPubMedGoogle Scholar
  10. Delmas PD, Meunier PJ (1997) The management of Paget's disease of bone. N Engl J Med 336:558–566CrossRefPubMedGoogle Scholar
  11. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138CrossRefPubMedGoogle Scholar
  12. Fleisher H (1997) Bisphosphonates: mechanisms of action and clinical use in osteoporosis–an update. Horm Metab Res 29:145–150CrossRefGoogle Scholar
  13. Fourier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544Google Scholar
  14. Fromigué O, Body JJ (2002) Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Investig 25:539–546Google Scholar
  15. Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC (1998) The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 273:34120–34127CrossRefPubMedGoogle Scholar
  16. Gibbs JB, Oliff A, Kohl NE (1994) Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77:175–178CrossRefPubMedGoogle Scholar
  17. Hasmim M, Bieler G, Rüegg C (2007) Zoledronate inhibits endothelial cell adhesion, migration and survival throught the suppression of multiple, prenylation-dependent signaling pathways. J Thromb Haemost 5:166–173Google Scholar
  18. Huber AV, Saleh L, Bauer S, Husslein P, Knöfler M (2006) TNF alpha-mediated induction of PAI-1 restricts invasion of HTR-8/SVneo trophoblast cells. Placenta 27:127–136CrossRefPubMedGoogle Scholar
  19. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478–1487CrossRefPubMedGoogle Scholar
  20. Ikebe T, Takeuchi H, Jimi E, Beppu M, Shinohara M, Shirasuna K (1998) Involvement of proteasomes in migration and matrix metalloproteinase-9 production of oral squamous cell carcinoma. Int J Cancer 77:578–585CrossRefPubMedGoogle Scholar
  21. Jilka RL, Takahashi K, Munshi M, Williams DC, Roberson PK, Manolagas SC (1998) Loss of estrogen upregulates osteoblastogenesis in the murine bone marrow. Evidence for autonomy from factors released during bone resorption. J Clin Invest 101:1942–1950CrossRefPubMedGoogle Scholar
  22. Kakiashvili E, Speight P, Waheed F, Seth R, Lodyga M, Tanimura S, Kohno M, Rotstein OD, Kapus A, Szászi K (2009) GEF-H1 mediates tumor necrosis factor-alpha-induced Rho activation and myosin phosphorylation: role in the regulation of tubular paracellular permeability. J Biol Chem 284:11454–1166CrossRefPubMedGoogle Scholar
  23. Kim YH, Kim GS, Jeong-Hwa B (2002) Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression. Exp Mol Med 34:145–151PubMedGoogle Scholar
  24. Kwak HB, Kim JY, Kim KJ, Choi MK, Kim JJ, Kim KM, Shin YI, Lee MS, Kim HS, Kim JW, Chun CH, Cho HJ, Hong GY, Juhng SK, Yoon KH, Park BH, Bae JM, Han JK, Oh J (2009) Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull 32:1193–1198CrossRefPubMedGoogle Scholar
  25. Lesclous P, Abi Najm S, Carrel JP, Baroukh B, Lombardi T, Willi JP, Rizzoli R, Saffar JL, Samson J (2009) Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone 45:843–852CrossRefPubMedGoogle Scholar
  26. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik P, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ (2000) RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566–1571CrossRefPubMedGoogle Scholar
  27. Liao TS, Yurgelun MB, Chang SS, Zhang HZ, Murakami K, Blaine TA, Parisien MV, Kim W, Winchester RJ, Lee FY (2005) Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J Orthop Res 23:203–209CrossRefPubMedGoogle Scholar
  28. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443CrossRefPubMedGoogle Scholar
  29. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589CrossRefPubMedGoogle Scholar
  30. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in overiohysterectomized beagle dogs effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768–1778CrossRefPubMedGoogle Scholar
  31. Nishikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugal N, Yamamoto M, Nagata N (1996) Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 18:9–14CrossRefPubMedGoogle Scholar
  32. Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF (1996) A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150–159CrossRefPubMedGoogle Scholar
  33. Porter KE, Turner NA, O'Regan DJ, Ball SG (2004) Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res 64:507–515CrossRefPubMedGoogle Scholar
  34. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 70:401–410CrossRefPubMedGoogle Scholar
  35. Roelofs AJ, Coxon FO, Ebetino FH, Lundy MW, Henneman ZJ, Nancollas GH, Sun S, Blazewska KM, Bala JL, Kashemirov BA, Khalid AB, Mckenna CE, Rogers MJ (2010) Fluorescent risedronate analogue reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 25:606–616CrossRefPubMedGoogle Scholar
  36. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9:2643–2658CrossRefPubMedGoogle Scholar
  37. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978CrossRefPubMedGoogle Scholar
  38. Roodman GD (1996) Paget's disease and osteoclast biology. Bone 9:209–212CrossRefGoogle Scholar
  39. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ (1993) Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 91:2004–2011CrossRefPubMedGoogle Scholar
  40. Schmitz AA, Govek EE, Böttner B, Van Aelst L (2000) Rho GTPases: signaling, migration, and invasion. Exp Cell Res 261:1–12CrossRefPubMedGoogle Scholar
  41. Seabra MC, James GL (1998) Prenylation assays for small GTPases. Methods Mol Biol 84:251–260PubMedGoogle Scholar
  42. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20:345–357CrossRefPubMedGoogle Scholar
  43. Takayanagi H (2007) Novel signaling pathways and therapeutic targets in osteoclasts. Adv Exp Med Biol 602:93–96CrossRefPubMedGoogle Scholar
  44. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochu T, Inoue J, Wagner EF, Mark TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3:889–901CrossRefPubMedGoogle Scholar
  45. Teitelbaum SL, Ross FP (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4:638–649CrossRefPubMedGoogle Scholar
  46. Tloczek AM, Blaszczyk-Brzezinska E (2009) IL-6, but not IL-4, stimulates chemokinesis and TNF stimulates chemotaxis of tissue mast cells: involvement of both mitogen-activated protein kinases and phosphatidylinositol 3-kinase signaling pathways. APMIS 117:558–567CrossRefGoogle Scholar
  47. Turner NA, Aley PK, Hall KT, Warburton P, Galloway S, Midgley L, O'Regan DJ, Wood IC, Ball SG, Porter KE (2007) Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. J Mol Cell Cardiol 43:168–176CrossRefPubMedGoogle Scholar
  48. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061CrossRefPubMedGoogle Scholar
  49. Yao Z, Li P, Zhang Q, Schwarz E, Keng P, Arbini A, Boyce AB, Xing L (2006) Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-fms expression. J Biol Chem 281:11846–11855CrossRefPubMedGoogle Scholar
  50. Zhang FL, Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241–269CrossRefPubMedGoogle Scholar
  51. Zhang C, Schmidt M, von Eichei-Streiber C, Jakobs KH (1996) Inhibition by toxin B of inositol phosphate formation induced by G protein-coupled and tyrosine kinase receptors in N1E-115 neuroblastoma cells: involvement of Rho proteins. Mol Pharmacol 50:864–869PubMedGoogle Scholar
  52. Zhang YH, Heulsmann A, Tondravi MM, Mukherjee A, Abu-Amer Y (2001) Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 276:563–568CrossRefPubMedGoogle Scholar
  53. Zhang Q, Guo R, Schwarz EM, Boyce BF, Xing L (2008) TNF inhibits production of stromal cell-derived factor 1 by bone stromal cells and increases osteoclast precursor mobilization from bone marrow to peripheral blood. Arthritis Res Ther 10:R37CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Keiichiro Kimachi
    • 1
    • 2
  • Hiroshi Kajiya
    • 1
    Email author
  • Shuji Nakayama
    • 1
    • 2
  • Tetsuro Ikebe
    • 2
  • Koji Okabe
    • 1
  1. 1.Department of Physiological Science and Molecular BiologyFukuoka Dental CollegeFukuokaJapan
  2. 2.Department of Oral and Maxillofacial SurgeryFukuoka Dental CollegeFukuokaJapan

Personalised recommendations